| [1] |
姜军. 乳腺癌综合治疗——乳腺癌外科治疗理念的发展及启示[J]. 中国实用外科杂志,2011,31(10):920-922.
|
| [2] |
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med,2002,347(16):1233-1241.
|
| [3] |
Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage Ⅰ-Ⅱbreast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial [J]. Lancet Oncol,2012,13(4):412-419.
|
| [4] |
No authors listed. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group [J]. N Engl J Med, 1995, 333(22):1444-1455.
|
| [5] |
Nijenhuis MV, Rutgers EJ. Who should not undergo breast conservation? [J]. Breast,2013,22 Suppl 2: S110-114.
|
| [6] |
周美琪, 邓甬川.乳腺癌保乳治疗的共识与争议[J]. 外科理论与实践,2014,19(5):372-376.
|
| [7] |
Zhang L, Jiang M, Zhou Y, et al. Survey on breast cancer patients in China toward breast-conserving surgery [J]. Psychooncology, 2012,21(5):488-495.
|
| [8] |
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer version 2.2015 [J].J Natl Compr Canc Netw,2015,13(4):448-475.
|
| [9] |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015 版)[J]. 中国癌症杂志,2015,25(9):692-754.
|
| [10] |
Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials[J]. Lancet, 2011, 378 (9804):1707-1716.
|
| [11] |
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med,2002,347(16):1233-1241.
|
| [12] |
Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer.[J]. N Engl J Med,1995,333(22):1456-1461.
|
| [13] |
郑新宇. 乳腺癌保乳手术切缘问题[J]. 中国实用外科杂志,2011,31(10):928-931.
|
| [14] |
Tang R,Coopey SB, Specht MC,et al. Lumpectomy specimen margins are not reliable in predicting residual disease in breast conserving surgery[J]. Am J Surg,2014,210(1):93-98.
|
| [15] |
Holland R, Veling SH, Mravunac M, et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breastconserving surgery [J]. Cancer,1985,56(5):979-990.
|
| [16] |
Houssami N, Macaskill P, Marinovich ML, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis[J]. Ann Surg Oncol,2014,21(3):717-730.
|
| [17] |
Houssami N, Macaskill P, Marinovich ML, et al. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy[J]. Eur J Cancer,2010,46(18):3219-3232.
|
| [18] |
Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰand Ⅱinvasive breast cancer[J]. Int J Radiat Oncol Biol Phys,2014,88(3):553-564.
|
| [19] |
Merrill AL, Coopey SB, Tang R, et al. Implications of new lumpectomy margin guidelines for breast-conserving surgery: changes in reexcision rates and predicted rates of residual tumor[J]. Ann Surg Oncol,2016,23(3):729-734.
|
| [20] |
Galimberti V, Maisonneuve P, Rotmensz N, et al. Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of Oncology[J]. Ann Surg,2011,253(3):580-584.
|
| [21] |
Buchholz TA, Somerfield MR, Griggs JJ, et al. Margins for breastconserving surgery with whole-breast irradiation in stage Ⅰand Ⅱinvasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline[J]. J Clin Oncol, 2014,32(14):1502-1506.
|
| [22] |
Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence [J]. J Clin Oncol,2000,18(8):1668-1675.
|
| [23] |
Holland R, Connolly JL, Gelman R, et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast [J]. J Clin Oncol,1990,8(1):113-118.
|
| [24] |
Chagpar AB, Killelea BK, Tsangaris TN, et al. A randomized,controlled trial of cavity shave margins in breast cancer [J]. N Engl J Med,2015,373(6):503-510.
|
| [25] |
Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer:10-year results of the randomized boost versus no boost EORTC 22881-10882 trial [J]. J Clin Oncol, 2007, 25(22):3259-3265.
|
| [26] |
Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial[J]. J Clin Oncol,2009,27(30):4939-4947.
|
| [27] |
Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials [J]. Lancet Oncol, 2013, 14 (11):1086-1094.
|
| [28] |
Fisher B, Dignam J,Mamounas EP,et al. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil[J]. J Clin Oncol,1996,14(7):1982-1992.
|
| [29] |
Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J]. J Natl Cancer Inst,1996,88(21):1529-1542.
|
| [30] |
Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J]. J Clin Oncol,1998,16(8):2672-2685.
|
| [31] |
Fisher B, Jeong JH, Anderson S, et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials[J]. J Natl Cancer Inst,2004,96 (24):1823-1831.
|
| [32] |
Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol,2006,24(13):2019-2027.
|
| [33] |
Demirci S, Broadwater G, Marks LB, et al. Breast conservation therapy: the influence of molecular subtype and margins [J]. Int J Radiat Oncol Biol Phys,2012,83(3):814-820.
|
| [34] |
Arvold ND, Taghian AG, Niemierko A, et al. Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy [J]. J Clin Oncol,2011,29(29):3885-3891.
|
| [35] |
Gangi A, Chung A, Mirocha J, et al. Breast-conserving therapy for triple-negative breast cancer [J]. JAMA Surg, 2014, 149 (3):252-258.
|
| [36] |
Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-negative breast cancer is not a contraindication for breast conservation[J]. Ann Surg Oncol,2011,18(11):3164-3173.
|
| [37] |
Dubsky P. Surgical management after neoadjuvant chemotherapy[J].Breast,2015,24 Suppl 1:S17.
|